https://charts.traderzeitung.de/phases/US36269B1052 string(1398) "{"isin":"US36269B1052","name":"Gain Therapeutics Inc","stock_id_xnas":17075644,"stock_id_xnys":null,"generated_at":"2026-09-24 01:32:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.83,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.95,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":6.5574},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.841,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-5.5897},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Gain Therapeutics Aktie News & Nachrichten

[WKN: A2QQZ4 | Symbol: GANX]

Realtimekurs

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Gain Therapeutics gefunden werden.

Gain Therapeutics Nachrichtenticker öffnen

MT Newswires 16.07.2026 14:22 Uhr

Gain Therapeutics ernennt Joanne Taylor zum Wissenschaftlichen Leiter, Terenzio Ignoni zum Chief Operating Officer

08:21 AM EDT, 07/16/2026 (MT Newswires) -- Gain Therapeutics (GANX) teilte am Donnerstag mit, dass es Joanne Taylor und Terenzio Ignoni in die Positio

MT Newswires 29.06.2026 22:37 Uhr

Gain Therapeutics erhält US-FDA-Zulassung, um GT-02287 in eine Phase-2-Studie für die Parkinson-Krankheit voranzutreiben

04:36 PM EDT, 06/29/2026 (MT Newswires) -- Gain Therapeutics (GANX) teilte am Montag mit, dass die US-amerikanische Food and Drug Administration (FDA)